Withdrawals due to adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (Panaccione 2010) · induction of remission in Crohn's disease
Briakinumab showed no clear difference in adverse events (Panaccione 2010) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawls due to adverse events · induction of remission in Crohn's disease
IL‐10 probably leads to higher withdrawls due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review